Missing Clinical Trial Data: "Mixed Model" Approach Gains Ground At FDA
Executive Summary
Clinical trial sponsors should adopt a mixed statistical model to cope with missing data rather than relying on the "last observation carried forward" model that was formerly perceived as regulators' favorite
You may also be interested in...
Forest’s Lexapro Okayed For Adolescents With Major Depressive Disorder
SSRI is only the second antidepressant approved for treatment in adolescents.
Lexapro Pediatric Depression Filing Planned In 2008
Forest and H. Lundbeck announced Phase III study results of the SSRI in adolescents aged 12 to 17.
Cellegy Seeks A Buyer Or Partner For Cellegesic Following FDA “Approvable” Letter
"Approvable" letter indicates the need for additional studies to provide more evidence of the efficacy of the nitroglycerin ointment for anal fissures.